Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology-Reference-Cited by-同舟云学术

Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacology

Published:2017-08-24 Issue: Volume: Page:
ISSN:0767-3981
Container-title:Fundamental & Clinical Pharmacology
language:en
Short-container-title:Fundam Clin Pharmacol

Author:

Micallef Joëlle¹²^ORCID,Boutouyrie Pierre³,Blin Olivier¹²

Affiliation:

1. Service de Pharmacologie Clinique et Pharmacovigilance, AP-HM; 13385 Marseille France

2. Pharmacologie intégrée et interface clinique et industriel; Orphandev-FCRIN; Institut des Neurosciences Timone - AMU-CNRS 7289; Aix Marseille Université; 13385 Marseille France

3. Service de Pharmacologie; HEGP; Assistance Publique Hôpitaux de Paris; Université Paris Descartes, Sorbonne Paris-cité, INSERM U970; 7598 Paris France

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/fcp.12314/fullpdf

Reference59 articles.

1. Why rare diseases are an important medical and social issue;Schieppati;Lancet,2008

2. Clinical pharmacology as a cornerstone of orphan drug development;Bashaw;Nat. Rev. Drug Discov.,2011

3. http://www.agence-nationale-recherche.fr/investissements-d-avenir/appels-a-projets/2010/infrastructures/

4. http://www.fcrin.org/en

5. http://www.euclid-ctu.eu/

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patients' organizations in rare diseases and involvement in drug information: Illustrations with LMC France, the French Association of Chronic Myeloid leukemia;THERAPIE;2020

2. The challenges of pharmacoepidemiology of orphan drugs in rare diseases;Therapies;2020-04

3. Pharmacovigilance and drug-induced rare diseases: Strengths of the French Network of Regional Pharmacovigilance Centres;Therapies;2020-04

4. An old drug for a rare disease: The example of celiprolol for vascular Ehlers-Danlos syndrome;Therapies;2020-04

5. Orphan drug clinical development;Therapies;2020-04